Identification of disease-relevant genes for molecularly-targeted drug discovery

Current Cancer Drug Targets

Volumn 12, Issue 1, 2012, Pages 1-13

  Kauselmann, G ^a   Dopazo, A ^b   Link, W ^c  

^a UNIVERSITY OF ALGARVE   (Portugal)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c TaconicArtemis GmbH   (Germany)

Author keywords

Analogue sensitive kinase alleles; Chemical genetics; Genetically engineered mice; High content screening; Imatinib; Target discovery; Target validation

Indexed keywords

CETUXIMAB; CYTOTOXIC AGENT; IMATINIB; PROTEIN KINASE; RITUXIMAB; TRANSCRIPTION FACTOR FOXO; TRASTUZUMAB; VEMURAFENIB;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL LINE; CHEMICAL GENETICS; CHORIOCARCINOMA; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; EXPERIMENTAL MODEL; GENE; GENOME; HODGKIN DISEASE; HUMAN; LYMPHOMA; MELANOMA; METASTATIC BREAST CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PHENOTYPE; POINT MUTATION; RNA INTERFERENCE; SCREENING; SIGNAL TRANSDUCTION; TESTIS CANCER; TRANSGENIC MOUSE; UNSPECIFIED SIDE EFFECT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GENETIC THERAPY; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84855851646     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912798888947     Document Type: Article

References (108)

1. Blagosklonny, M. V. Matching targets for selective cancer therapy. Drug Discov. Today 2003, 8, 1104-1107.
2. Gibbs, J. B. Mechanism-based target identification and drug discovery in cancer research. Science 2000, 287, 1969-1973.
3. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
4. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
5. Savage, P.; Stebbing, J.; Bower, M.; Crook, T. Why does cytotoxic chemotherapy cure only some cancers? Nat. Clin Pract. Oncol. 2009, 6, 43-52.
6. Haber, D. A.; Gray, N. S.; Baselga, J. The evolving war on cancer. Cell 2011, 145, 19-24.
7. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 2002, 1, 493-502.
8. Druker, B. J. Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. 2004, 91, 1-30.
9. Druker, B. J. Perspectives on the development of imatinib and the future of cancer research. Nat. Med. 2009, 15, 1149-1152.
10. Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; O'Dwyer, P. J.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363, 809-819.
11. Kaelin, W. G., Jr. Gleevec: prototype or outlier? Sci. STKE 2004, 2004, pe12.
12. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293, 876-880.
13. Apsel, B.; Blair, J. A.; Gonzalez, B.; Nazif, T. M.; Feldman, M. E.; Aizenstein, B.; Hoffman, R.; Williams, R. L.; Shokat, K. M.; Knight, Z. A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 2008, 4, 691-699.
14. Fan, Q. W.; Cheng, C. K.; Nicolaides, T. P.; Hackett, C. S.; Knight, Z. A.; Shokat, K. M.; Weiss, W. A. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 2007, 67, 7960-7965.
15. Haigis, K. M.; Kendall, K. R.; Wang, Y.; Cheung, A.; Haigis, M. C.; Glickman, J. N.; Niwa-Kawakita, M.; Sweet-Cordero, A.; Sebolt-Leopold, J.; Shannon, K. M.; Settleman, J.; Giovannini, M.; Jacks, T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 2008, 40, 600-608.
16. Solit, D. B.; Garraway, L. A.; Pratilas, C. A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J. M.; She, Y.; Osman, I.; Golub, T. R.; Sebolt-Leopold, J.; Sellers, W. R.; Rosen, N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439, 358-362.
17. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455, 1061-1068.
18. Jones, D. Pathways to cancer therapy. Nat. Rev. Drug Discov. 2008, 7, 875-876.
19. Jones, S.; Zhang, X.; Parsons, D. W.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Kamiyama, H.; Jimeno, A.; Hong, S. M.; Fu, B.; Lin, M. T.; Calhoun, E. S.; Kamiyama, M.; Walter, K.; Nikolskaya, T.; Nikolsky, Y.; Hartigan, J.; Smith, D. R.; Hidalgo, M.; Leach, S. D.; Klein, A. P.; Jaffee, E. M.; Goggins, M.; Maitra, A.; Iacobuzio-Donahue, C.; Eshleman, J. R.; Kern, S. E.; Hruban, R. H.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321, 1801-1806.
20. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I. M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A., Jr.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K.; Shinjo, S. M.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321, 1807-1812.
21. Baldwin, A.; Li, W.; Grace, M.; Pearlberg, J.; Harlow, E.; Munger, K.; Grueneberg, D. A. Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc. Natl. Acad. Sci. U.S. A 2008, 105, 16478-16483.
22. Barbie, D. A.; Tamayo, P.; Boehm, J. S.; Kim, S. Y.; Moody, S. E.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Meylan, E.; Scholl, C.; Frohling, S.; Chan, E. M.; Sos, M. L.; Michel, K.; Mermel, C.; Silver, S. J.; Weir, B. A.; Reiling, J. H.; Sheng, Q.; Gupta, P. B.; Wadlow, R. C.; Le, H.; Hoersch, S.; Wittner, B. S.; Ramaswamy, S.; Livingston, D. M.; Sabatini, D. M.; Meyerson, M.; Thomas, R. K.; Lander, E. S.; Mesirov, J. P.; Root, D. E.; Gilliland, D. G.; Jacks, T.; Hahn, W. C. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462, 108-112.
23. Grueneberg, D. A.; Degot, S.; Pearlberg, J.; Li, W.; Davies, J. E.; Baldwin, A.; Endege, W.; Doench, J.; Sawyer, J.; Hu, Y.; Boyce, F.; Xian, J.; Munger, K.; Harlow, E. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 16472-16477.
24. Luo, J.; Emanuele, M. J.; Li, D.; Creighton, C. J.; Schlabach, M. R.; Westbrook, T. F.; Wong, K. K.; Elledge, S. J. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009, 137, 835-848.
25. Manning, B. D. Challenges and opportunities in defining the essential cancer kinome. Sci. Signal. 2009, 2, pe15.
26. Scholl, C.; Frohling, S.; Dunn, I. F.; Schinzel, A. C.; Barbie, D. A.; Kim, S. Y.; Silver, S. J.; Tamayo, P.; Wadlow, R. C.; Ramaswamy, S.; Dohner, K.; Bullinger, L.; Sandy, P.; Boehm, J. S.; Root, D. E.; Jacks, T.; Hahn, W. C.; Gilliland, D. G. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009, 137, 821-834.
27. Abraham, V. C.; Taylor, D. L.; Haskins, J. R. High content screening applied to large-scale cell biology. Trends Biotechnol. 2004, 22, 15-22.
28. Zanella, F.; Lorens, J. B.; Link, W. High content screening: seeing is believing. Trends Biotechnol. 2010, 28, 237-245.
29. Link, W.; Oyarzabal, J.; Serelde, B. G.; Albarran, M. I.; Rabal, O.; Cebria, A.; Alfonso, P.; Fominaya, J.; Renner, O.; Peregrina, S.; Soilan, D.; Ceballos, P. A.; Hernandez, A. I.; Lorenzo, M.; Pevarello, P.; Granda, T. G.; Kurz, G.; Carnero, A.; Bischoff, J. R. Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases. J. Biol. Chem. 2009, 284, 28392-28400.
30. Stockwell, B. R. Exploring biology with small organic molecules. Nature 2004, 432, 846-854.
31. Bain, J.; Plater, L.; Elliott, M.; Shpiro, N.; Hastie, C. J.; McLauchlan, H.; Klevernic, I.; Arthur, J. S.; Alessi, D. R.; Cohen, P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408, 297-315.
32. Alessi, D. R.; James, S. R.; Downes, C. P.; Holmes, A. B.; Gaffney, P. R.; Reese, C. B.; Cohen, P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 1997, 7, 261-269
33. Workman, P.; Collins, I. Probing the probes: fitness factors for small molecule tools. Chem. Biol. 2010, 17, 561-577.
34. Kalen, M.; Wallgard, E.; Asker, N.; Nasevicius, A.; Athley, E.; Billgren, E.; Larson, J. D.; Wadman, S. A.; Norseng, E.; Clark, K. J.; He, L.; Karlsson-Lindahl, L.; Hager, A. K.; Weber, H.; Augustin, H.; Samuelsson, T.; Kemmet, C. K.; Utesch, C. M.; Essner, J. J.; Hackett, P. B.; Hellstrom, M. Combination of reverse and chemical genetic screens reveals angiogenesis inhibitors and targets. Chem. Biol. 2009, 16, 432-441.
35. Norton, J. T.; Titus, S. A.; Dexter, D.; Austin, C. P.; Zheng, W.; Huang, S. Automated High-Content Screening for Compounds That Disassemble the Perinucleolar Compartment. J. Biomol. Screen. 2009.
36. Raccor, B. S.; Vogt, A.; Sikorski, R. P.; Madiraju, C.; Balachandran, R.; Montgomery, K.; Shin, Y.; Fukui, Y.; Jung, W. H.; Curran, D. P.; Day, B. W. Cell-based and biochemical structure-activity analyses of analogs of the microtubule stabilizer dictyostatin. Mol. Pharmacol. 2008, 73, 718-726.
37. Mani, R.; St. Onge, R. P.; Hartman, J. L.T.; Giaever, G.; Roth, F. P. Defining genetic interaction. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3461-3466.
38. Chen, S.; Borowiak, M.; Fox, J. L.; Maehr, R.; Osafune, K.; Davidow, L.; Lam, K.; Peng, L. F.; Schreiber, S. L.; Rubin, L. L.; Melton, D. A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat. Chem. Biol. 2009, 5, 258-265.
39. Zhu, S.; Wurdak, H.; Wang, J.; Lyssiotis, C. A.; Peters, E. C.; Cho, C. Y.; Wu, X.; Schultz, P. G. A small molecule primes embryonic stem cells for differentiation. Cell Stem Cell 2009, 4, 416-426.
40. Warashina, M.; Min, K. H.; Kuwabara, T.; Huynh, A.; Gage, F. H.; Schultz, P. G.; Ding, S. A synthetic small molecule that induces neuronal differentiation of adult hippocampal neural progenitor cells. Angew Chem. Int. Ed. Engl. 2006, 45, 591-593.
41. Bushway, P. J.; Mercola, M. High-throughput screening for modulators of stem cell differentiation. Methods Enzymol. 2006, 414, 300-316.
42. Ichida, J. K.; Blanchard, J.; Lam, K.; Son, E. Y.; Chung, J. E.; Egli, D.; Loh, K. M.; Carter, A. C.; Di Giorgio, F. P.; Koszka, K.; Huangfu, D.; Akutsu, H.; Liu, D. R.; Rubin, L. L.; Eggan, K. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell 2009, 5, 491-503.
43. Novina, C. D.; Sharp, P. A. The RNAi revolution. Nature 2004, 430, 161-164.
44. Moffat, J.; Grueneberg, D. A.; Yang, X.; Kim, S. Y.; Kloepfer, A. M.; Hinkle, G.; Piqani, B.; Eisenhaure, T. M.; Luo, B.; Grenier, J. K.; Carpenter, A. E.; Foo, S. Y.; Stewart, S. A.; Stockwell, B. R.; Hacohen, N.; Hahn, W. C.; Lander, E. S.; Sabatini, D. M.; Root, D. E. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006, 124, 1283-1298.
45. Draviam, V. M.; Stegmeier, F.; Nalepa, G.; Sowa, M. E.; Chen, J.; Liang, A.; Hannon, G. J.; Sorger, P. K.; Harper, J. W.; Elledge, S. J. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat. Cell Biol. 2007, 9, 556-564.
46. Rines, D. R.; Gomez-Ferreria, M. A.; Zhou, Y.; DeJesus, P.; Grob, S.; Batalov, S.; Labow, M.; Huesken, D.; Mickanin, C.; Hall, J.; Reinhardt, M.; Natt, F.; Lange, J.; Sharp, D. J.; Chanda, S. K.; Caldwell, J. S. Whole genome functional analysis identifies novel components required for mitotic spindle integrity in human cells. Genome Biol. 2008, 9, R44.
47. Prudencio, M.; Rodrigues, C. D.; Hannus, M.; Martin, C.; Real, E.; Goncalves, L. A.; Carret, C.; Dorkin, R.; Rohl, I.; Jahn-Hoffmann, K.; Luty, A. J.; Sauerwein, R.; Echeverri, C. J.; Mota, M. M. Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection. PLoS Pathog. 2008, 4, e1000201.
48. Krishnan, M. N.; Ng, A.; Sukumaran, B.; Gilfoy, F. D.; Uchil, P. D.; Sultana, H.; Brass, A. L.; Adametz, R.; Tsui, M.; Qian, F.; Montgomery, R. R.; Lev, S.; Mason, P. W.; Koski, R. A.; Elledge, S. J.; Xavier, R. J.; Agaisse, H.; Fikrig, E. RNA interference screen for human genes associated with West Nile virus infection. Nature 2008, 455, 242-245.
49. Carnero, A.; Blanco-Aparicio, C.; Renner, O.; Link, W.; Leal, J. F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 2008, 8, 187-198.
50. Engelman, J. A. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer 2009, 9, 550-562.
51. Garcia-Echeverria, C.; Sellers, W. R. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008, 27, 5511-5526.
52. Fu, Z.; Tindall, D. J. FOXOs, cancer and regulation of apoptosis. Oncogene 2008, 27, 2312-2319.
53. Zanella, F.; Link, W.; Carnero, A. Understanding FOXO, New Views on Old Transcription Factors. Curr. Cancer Drug Targets 2010.
54. Dansen, T. B.; Burgering, B. M. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008, 18, 421-429.
55. Zanella, F.; Rosado, A.; Garcia, B.; Carnero, A.; Link, W. Chemical genetic analysis of FOXO nuclear-cytoplasmic shuttling by using image-based cell screening. Chembiochem. 2008, 9, 2229-2237.
56. Link, W. The Therapeutic Potential of FOXO Proteins. Curr. Drug Targets 2011.
57. Link, W. Context-dependent therapeutic potential of FOXO proteins in oral squamous cell carcinoma. Oral Oncol. 2011, 47, 229-230.
58. Rosado, A.; Zanella, F.; Garcia, B.; Carnero, A.; Link, W. A dualcolor fluorescence-based platform to identify selective inhibitors of Akt signaling. PLoS ONE 2008, 3, e1823.
59. Zanella, F.; Rosado, A.; Blanco, F.; Henderson, B. R.; Carnero, A.; Link, W. An HTS approach to screen for antagonists of the nuclear export machinery using high content cell-based assays. Assay Drug Dev. Technol. 2007, 5, 333-341.
60. Kau, T. R.; Schroeder, F.; Ramaswamy, S.; Wojciechowski, C. L.; Zhao, J. J.; Roberts, T. M.; Clardy, J.; Sellers, W. R.; Silver, P. A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003, 4, 463-476.
61. Nishi, N.; Tanabe, H.; Oya, H.; Urushihara, M.; Miyanaka, H.; Wada, F. Identification of probasin-related antigen as cystathionine gamma-lyase by molecular cloning. J. Biol. Chem. 1994, 269, 1015-1019.
62. Kim, D. H.; Shin, J.; Kwon, H. J. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp. Mol. Med. 2007, 39, 47-55.
63. Ahn, M. Y.; Jung, J. H.; Na, Y. J.; Kim, H. S. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol. Oncol. 2008, 108, 27-33.
64. Zanella, F.; Rosado, A.; Garcia, B.; Carnero, A.; Link, W. Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. BMC Cell Biol. 2009, 10, 14.
65. Soengas, M. S.; Lowe, S. W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22, 3138-3151.
66. Grandinetti, K. B.; Stevens, T. A.; Ha, S.; Salamone, R. J.; Walker, J. R.; Zhang, J.; Agarwalla, S.; Tenen, D. G.; Peters, E. C.; Reddy, V. A. Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPalpha. Oncogene 2011.
67. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 2004, 3, 711-715.
68. Sams-Dodd, F. Target-based drug discovery: is something wrong? Drug Discov. Today 2005, 10, 139-147.
69. Booth, B.; Glassman, R.; Ma, P. Oncology's trials. Nat. Rev. Drug Discov. 2003, 2, 609-610.
70. Klastersky, J. Adverse effects of the humanized antibodies used as cancer therapeutics. Curr. Opin. Oncol. 2006, 18, 316-320.
71. Peerzada, M. M.; Spiro, T. P.; Daw, H. A. Pulmonary toxicities of biologics: a review. Anticancer Drugs 2010, 21, 131-139.
72. Wu, P. A.; Balagula, Y.; Lacouture, M. E.; Anadkat, M. J. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr. Opin. Oncol. 2011, 23, 343-351.
73. Habeck, H.; Odenthal, J.; Walderich, B.; Maischein, H.; Schulte-Merker, S. Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. Curr. Biol. 2002, 12, 1405-1412.
74. Frese, K. K.; Tuveson, D. A. Maximizing mouse cancer models. Nat. Rev. Cancer 2007, 7, 645-658.
75. Kendall, S. D.; Adam, S. J.; Counter, C. M. Genetically engineered human cancer models utilizing mammalian transgene expression. Cell Cycle 2006, 5, 1074-1079.
76. Becher, O. J.; Holland, E. C. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 2006, 66, 3355-3358, discussion 3358-3359.
77. Heisterkamp, N.; Jenster, G.; ten Hoeve, J.; Zovich, D.; Pattengale, P. K.; Groffen, J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990, 344, 251-253.
78. Hutchinson, J. N.; Muller, W. J. Transgenic mouse models of human breast cancer. Oncogene 2000, 19, 6130-6137.
79. Santos, J.; Fernandez-Navarro, P.; Villa-Morales, M.; Gonzalez-Sanchez, L.; Fernandez-Piqueras, J. Genetically modified mouse models in cancer studies. Clin. Transl. Oncol. 2008, 10, 794-803.
80. Scheer, N.; Ross, J.; Rode, A.; Zevnik, B.; Niehaves, S.; Faust, N.; Wolf, C. R. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J. Clin. Invest. 2008, 118, 3228-3239.
81. Hasegawa, M.; Kapelyukh, Y.; Tahara, H.; Seibler, J.; Rode, A.; Krueger, S.; Lee, D. N.; Wolf, C. R.; Scheer, N. Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol. Pharmacol. 2011.
82. Johnson, L.; Mercer, K.; Greenbaum, D.; Bronson, R. T.; Crowley, D.; Tuveson, D. A.; Jacks, T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410, 1111-1116.
83. Singh, M.; Lima, A.; Molina, R.; Hamilton, P.; Clermont, A. C.; Devasthali, V.; Thompson, J. D.; Cheng, J. H.; Bou Reslan, H.; Ho, C. C.; Cao, T. C.; Lee, C. V.; Nannini, M. A.; Fuh, G.; Carano, R. A.; Koeppen, H.; Yu, R. X.; Forrest, W. F.; Plowman, G. D.; Johnson, L. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 2010, 28, 585-593.
84. Skvorak, K.; Vissel, B.; Homanics, G. E. Production of conditional point mutant knockin mice. Genesis 2006, 44, 345-353.
85. Thornton, T. M.; Pedraza-Alva, G.; Deng, B.; Wood, C. D.; Aronshtam, A.; Clements, J. L.; Sabio, G.; Davis, R. J.; Matthews, D. E.; Doble, B.; Rincon, M. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008, 320, 667-670.
86. Bruning, J. C.; Gautam, D.; Burks, D. J.; Gillette, J.; Schubert, M.; Orban, P. C.; Klein, R.; Krone, W.; Muller-Wieland, D.; Kahn, C. R. Role of brain insulin receptor in control of body weight and reproduction. Science 2000, 289, 2122-2125.
87. Ashall, L.; Horton, C. A.; Nelson, D. E.; Paszek, P.; Harper, C. V.; Sillitoe, K.; Ryan, S.; Spiller, D. G.; Unitt, J. F.; Broomhead, D. S.; Kell, D. B.; Rand, D. A.; See, V.; White, M. R. Pulsatile stimulation determines timing and specificity of NF-kappaBdependent transcription. Science 2009, 324, 242-246.
88. Phiel, C. J.; Wilson, C. A.; Lee, V. M.; Klein, P. S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423, 435-439.
89. Cowan-Jacob, S. W.; Mobitz, H.; Fabbro, D. Structural biology contributions to tyrosine kinase drug discovery. Curr. Opin. Cell Biol. 2009, 21, 280-287.
90. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303, 1800-1805.
91. Knight, Z. A. Small Molecule Inhibitors of the PI3-Kinase Family. Curr. Top. Microbiol. Immunol. 2010.
92. Pawson, T.; Kofler, M. Kinome signaling through regulated protein-protein interactions in normal and cancer cells. Curr. Opin. Cell Biol. 2009, 21, 147-153.
93. Poole, A. W.; Pula, G.; Hers, I.; Crosby, D.; Jones, M. L. PKCinteracting proteins: from function to pharmacology. Trends Pharmacol. Sci. 2004, 25, 528-535.
94. Tseng, P. H.; Wang, Y. C.; Weng, S. C.; Weng, J. R.; Chen, C. S.; Brueggemeier, R. W.; Shapiro, C. L.; Chen, C. Y.; Dunn, S. E.; Pollak, M. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxibderived phosphoinositide-dependent kinase-1 inhibitor. Mol. Pharmacol. 2006, 70, 1534-1541.
95. O'Malley, D. P.; Orazi, A.; Dunphy, C. H.; Coleman, B. R.; Marks, R. A.; Wang, M.; Cheng, L. Loss of heterozygosity identifies genetic changes in chronic myeloid disorders, including myeloproliferative disorders, myelodysplastic syndromes and chronic myelomonocytic leukemia. Mod. Pathol. 2007, 20, 1166-1171.
96. Quintas-Cardama, A.; Cortes, J. E.; Kantarjian, H. M. Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: Long-term implications. Cancer 2011.
97. Schnutgen, F.; Doerflinger, N.; Calleja, C.; Wendling, O.; Chambon, P.; Ghyselinck, N. B. A directional strategy for monitoring Cre-mediated recombination at the cellular level in the mouse. Nat. Biotechnol. 2003, 21, 562-565.
98. Bishop, A. C.; Ubersax, J. A.; Petsch, D. T.; Matheos, D. P.; Gray, N. S.; Blethrow, J.; Shimizu, E.; Tsien, J. Z.; Schultz, P. G.; Rose, M. D.; Wood, J. L.; Morgan, D. O.; Shokat, K. M. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000, 407, 395-401.
99. Liu, Y.; Shah, K.; Yang, F.; Witucki, L.; Shokat, K. M. A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src. Bioorg. Med. Chem. 1998, 6, 1219-1226.
100. Barberi, T.; Klivenyi, P.; Calingasan, N. Y.; Lee, H.; Kawamata, H.; Loonam, K.; Perrier, A. L.; Bruses, J.; Rubio, M. E.; Topf, N.; Tabar, V.; Harrison, N. L.; Beal, M. F.; Moore, M. A.; Studer, L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat. Biotechnol. 2003, 21, 1200-1207.
101. Bariohay, B.; Roux, J.; Tardivel, C.; Trouslard, J.; Jean, A.; Lebrun, B. Brain-derived neurotrophic factor/tropomyosin-related kinase receptor type B signaling is a downstream effector of the brainstem melanocortin system in food intake control. Endocrinology 2009, 150, 2646-2653.
102. Chen, X.; Ye, H.; Kuruvilla, R.; Ramanan, N.; Scangos, K. W.; Zhang, C.; Johnson, N. M.; England, P. M.; Shokat, K. M.; Ginty, D. D. A chemical-genetic approach to studying neurotrophin signaling. Neuron 2005, 46, 13-21.
103. Heck, S.; Qian, X.; Velleca, M. Genetically engineered mouse models for drug discovery: new chemical genetic approaches. Curr. Drug Discov. Technol. 2004, 1, 13-26.
104. Morgan, D. J.; Weisenhaus, M.; Shum, S.; Su, T.; Zheng, R.; Zhang, C.; Shokat, K. M.; Hille, B.; Babcock, D. F.; McKnight, G. S. Tissue-specific PKA inhibition using a chemical genetic approach and its application to studies on sperm capacitation. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 20740-20745.
105. Wang, H.; Shimizu, E.; Tang, Y. P.; Cho, M.; Kyin, M.; Zuo, W.; Robinson, D. A.; Alaimo, P. J.; Zhang, C.; Morimoto, H.; Zhuo, M.; Feng, R.; Shokat, K. M.; Tsien, J. Z. Inducible protein knockout reveals temporal requirement of CaMKII reactivation for memory consolidation in the brain. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4287-4292.
106. Li, A. G.; Piluso, L. G.; Cai, X.; Wei, G.; Sellers, W. R.; Liu, X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol. Cell, 2006, 23, 575-587.
107. Shinozawa, T.; Tsuji, A.; Imahashi, K.; Nakashima, K.; Sawada, H.; Toyoshiba, H.; Yamamoto, S.; Takami, K.; Imai, R. Gene expression profiling of functional murine embryonic stem cellderived cardiomyocytes and comparison with adult heart: profiling of murine ESC-derived cardiomyocytes. J. Biomol. Screen. 2009, 14, 239-245.
108. Zanella, F.; Renner, O.; Garcia, B.; Callejas, S.; Dopazo, A.; Peregrina, S.; Carnero, A.; Link, W. Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. Oncogene 2010.